NanoViricides, Inc. (NASDAQ:NNVC) |

• NanoViricides announced on September 8, 2026, that it registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo Ebola virus. • The trial is listed in the Pan African Clinical Trials Database to address the expanding Ebola outbreak in the Democratic Republic of Congo.

• New artificial intelligence tools including specialized large language models and AI-assisted CT scans are being integrated into oncology care to improve early detection and pathology. • ChatGPT Health now allows patients to connect medical records and wellness apps to their AI experience to assist with health-related decisions.

• Superluminal and AusperBio secured venture capital funding in early 2026. • Superluminal raised $60 million while AusperBio added $120 million to its funding.

• Pharmaceutical companies are rebounding as clarity emerges regarding U.S. drug pricing regulations. • Diversified firms like Johnson & Johnson (JNJ) and AstraZeneca (AZN) are utilizing strong research and development pipelines to offset looming patent cliffs, which occur when exclusive rights to a drug expire.

• The FDA approved Rasonque, a new pancreatic cancer drug developed by Revolution Medicines. • Patients seeking the treatment have found that insurance coverage can take several weeks to catch up with the official approval.

• European biomedical innovation is declining as clinical trials and investment shift toward other global regions. • The region previously led the world in pharmaceutical research and delivered medical advances that transformed millions of lives.

• The FDA recently approved the intravenous antibiotic fosfomycin, marketed as Contepo, for adults with complicated urinary tract infections. • This medication targets infections caused by resistant Gram-negative pathogens, which are bacteria that resist common antibiotic treatments.

• Assort Health raised $120 million in a funding round to expand its AI-driven healthcare tools. • The company secured $120 million to scale its operations and technology.

• COVID-19 cases are increasing across at least 45 U.S. states as the summer season ends. • The rise in activity is occurring nationwide, though specific regional case numbers were not provided.

• Infectious disease specialists and Democratic lawmakers are opposing a Trump administration plan to eliminate a clinical research unit at the National Institute of Allergy and Infectious Diseases. • The Infectious Diseases Society of America and the HIV Medicine Association cited an August 28 notice from the National Institutes of Health that provided few details and a five-day comment period.

• The FDA approved a new cancer drug from Revolution Medicines last week after founder Greg Verdine spent 14 years developing the treatment. • Former Senator Ben Sasse, who has stage 4 pancreatic cancer, called the daily pill a "miracle" for shrinking his tumor volume and reducing pain.